Pharmaceutical - Boehringer Ingelheim

Filter

Current filters:

Boehringer Ingelheim

Popular Filters

1 to 25 of 196 results

Novartis, Boehringer and Celgene present new psoriasis data at AAD meeting

Novartis, Boehringer and Celgene present new psoriasis data at AAD meeting

23-03-2015

Novartis, Boehringer Ingelheim and Celgene have presented positive data on their dermatology products…

Boehringer IngelheimCelgene CorpCosentyxDermatologicalsNovartisOtezlaPharmaceuticalResearchStelara

FDA approves Boehringer Ingelheim and Eli Lilly's Glyxambi for type 2 diabetes

FDA approves Boehringer Ingelheim and Eli Lilly's Glyxambi for type 2 diabetes

02-02-2015

The US Food and Drug Administration has approved Glyxambi (empagliflozin/linagliptin) tablets from German…

Boehringer IngelheimDiabetesEli LillyGlyxambiPharmaceuticalRegulation

NICE set to recommend Boehringer’s type 2 diabetes drug Jardiance

NICE set to recommend Boehringer’s type 2 diabetes drug Jardiance

22-01-2015

England’s health care costs watchdog the National Institute for Health and Care Excellence (NICE) has…

Boehringer IngelheimDiabetesJardiancePharmaceuticalPricingRegulationUK

Boehringer’s Ofev approved in EU for the treatment of IPF

19-01-2015

German family-owned pharma major Boehringer Ingelheim revealed today that the European Commission has…

Boehringer IngelheimEuropeOfevPharmaceuticalRegulationRespiratory and Pulmonary

Sanofi enters strategic agreement with Boehringer Ingelheim on monoclonal antibodies

Sanofi enters strategic agreement with Boehringer Ingelheim on monoclonal antibodies

15-01-2015

French pharma major Sanofi has entered into a strategic agreement with German family-owned peer Boehringer…

Boehringer IngelheimGermanyLicensingPharmaceuticalResearchSanofi

Boehringer Ingelheim, Janssen and Novartis among partners teaming up for Alzheimer's research

Boehringer Ingelheim, Janssen and Novartis among partners teaming up for Alzheimer's research

15-01-2015

German family-owned drug major Boehringer Ingelheim is one of 35 partners from industry and academia…

AmgenBoehringer IngelheimEuropeJanssenNeurologicalNovartisPharmaceuticalResearch

Boehringer opts to take up rights to Oxford BioThera’s oncology target

Boehringer opts to take up rights to Oxford BioThera’s oncology target

14-01-2015

Privately-held, UK-based Oxford BioTherapeutics says that German family-owned pharma major Boehringer…

Boehringer IngelheimLicensingOncologyOxford BioTherapeuticsPharmaceuticalUK

Boehringer Ingelheim enters research pact with Yale University

Boehringer Ingelheim enters research pact with Yale University

14-01-2015

German family-owned pharma major Boehringer Ingelheim has entered into a collaboration with Yale University,…

Boehringer IngelheimGermanyImmunologicalsOncologyPharmaceuticalResearchRespiratory and Pulmonary

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

17-12-2014

In final guidance published today, UK health cost watchdog the National Institute for Health and Care…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

Boehringer’s Vargatef gains approval in EU for lung cancer

Boehringer’s Vargatef gains approval in EU for lung cancer

28-11-2014

The European Commission has granted EU marketing authorization for German family-owned pharma major Boehringer…

Boehringer IngelheimEuropeOncologyPharmaceuticalRegulationVargatef

Despite patent cliffs, pharma market shows signs of stability

19-11-2014

The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies…

Biogen IdecBoehringer IngelheimFinancialJohnson & JohnsonPatentsPfizerPharmaceutical

Added benefit of Jardiance not proven, says IQWiG

19-11-2014

Following an examination as to whether Jardiance (empagliflozin) offers an added benefit over appropriate…

Boehringer IngelheimDiabetesEli LillyGermanyJardiancePharmaceuticalPricingRegulation

Positive early results for Boehringer Ingelheim’s investigational antidote idarucizumab

19-11-2014

The US subsidiary of German family-owned pharma major Boehringer Ingelheim has presented Phase I study…

Boehringer IngelheimCardio-vascularHematologyidarucizumabPharmaceuticalPradaxaResearch

Boehringer Ingelheim start Phase III trial on idarucizumab as antidote to Pradaxa

Boehringer Ingelheim start Phase III trial on idarucizumab as antidote to Pradaxa

12-11-2014

German family-owned drug major Boehringer Ingelheim has initiated a global Phase III study on idarucizumab,…

Boehringer IngelheimHematologyidarucizumabPharmaceuticalPradaxaResearch

Boehringer Ingelheim's Spiriva Respimat NDA for asthma accepted for review by FDA

Boehringer Ingelheim's Spiriva Respimat NDA for asthma accepted for review by FDA

04-11-2014

German family-owned drug major Boehringer Ingelheim has had its Spiriva Respimat (tiotropium bromide)…

Boehringer IngelheimGermanyPharmaceuticalRegulationRespiratory and PulmonarySpirivaSpiriva Respimat

FDA study shows Pradaxa reduces stroke risk but raises chances of GI bleeding

FDA study shows Pradaxa reduces stroke risk but raises chances of GI bleeding

03-11-2014

A study carried out by the US Food and Drug Administration on Pradaxa (dabigatran etexilate mesylate)…

Boehringer IngelheimHematologyPharmaceuticalPradaxaRegulationResearchUSAWarfarin Sodium

NICE recommends Pradaxa for DVT and PE

NICE recommends Pradaxa for DVT and PE

31-10-2014

In draft guidance published today, the UK health costs watchdog the National Institute for Health and…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

Boehringer Ingelheim and Lilly revise diabetes alliance in certain countries

29-10-2014

In a move that will strengthen their 2011 alliance by enhancing efficiencies and enabling greater focus…

Boehringer IngelheimDiabetesEli LillyJardianceJentaduetoLicensingMarkets & MarketingPharmaceuticalTrajenta

US FDA approves Genentech’s Esbriet and Boehringer Ingelheim’s Ofev for IPF

US FDA approves Genentech’s Esbriet and Boehringer Ingelheim’s Ofev for IPF

16-10-2014

The US Food and Drug Administration has approved Esbriet (pirfenidone), from Roche subsidiary Genentech,…

Boehringer IngelheimEsbrietGenentechnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

Boehringer Ingelheim gets two drugs approved by Scotland’s health watchdog

14-10-2014

The UK subsidiary of German family-owned pharma major Boehringer Ingelheim announced today that, following…

Boehringer IngelheimCardio-vascularDiabetesJardiancePharmaceuticalPradaxaPricingUK

1 to 25 of 196 results

Back to top